nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2004 | Original Article

Diagnosis of suspected Alzheimer’s disease is improved by automated analysis of regional cerebral blood flow

verfasst von: Bich-Ngoc-Thanh Tang, Satoshi Minoshima, Jean George, Annie Robert, Christian Swine, Patrice Laloux, Thierry Vander Borght

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Accurate diagnosis of Alzheimer’s disease (AD), the most common form of dementia, remains difficult. In order to assess whether fully automated stereotactic surface projection (3D-SSP) presentation contributes to the diagnosis of AD by single-photon emission computed tomography (SPECT), we investigated the diagnostic accuracy of transaxial display with and without 3D-SSP analysis as well as the correlation between cerebral perfusion in different cortical areas and the mini mental score (MMS).

Methods

Seventy-two patients referred because of cognitive impairment were included in the study. According to the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s disease and Related Disorders Association (ADRDA) criteria, 27 patients were diagnosed as having probable AD while 45 were classified as non-AD patients. 3D-SSP was used to quantify the regional cerebral blood flow (rCBF) acquired from SPECT imaging.

Results

Compared with the transaxial section presentation alone, 3D-SSP presentation improved the area under the receiver operating curve (p<0.05) as well as intra-observer (k=0.73 vs 0.88) and inter-observer (k=0.50 vs 0.84) reproducibility. Upon normalisation of regional to thalamic activity, multiple regression analysis revealed a strong correlation between the MMS and rCBF in the right parietal cortex (p=0.002).

Conclusion

Addition of 3D-SSP to the transaxial section display of ECD-SPECT studies improves the reproducibility and the diagnostic performance in respect of AD in patients with cognitive impairment and provides a valid tool for assessment of the severity of cortical perfusion abnormalities in such patients.

Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. J Am Med Assoc 1997;278:1363–71.CrossRef

Lautenschlager N, Foley EJ, Haupt M, Zimmer R, Farrer LA, Kurz A. A systematic genetic-epidemiologic family study of patients with Alzheimer disease—experience with the MIRAGE study in Germany. Z Gerontol 1994;27:341–5.PubMed

Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 2001;15:169–73.CrossRefPubMed

Messa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer’s disease: comparison with fluorine-18-FDG PET. J Nucl Med 1994;35:210–6.PubMed

Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, et al. HMPAO SPET and FDG PET in Alzheimer’s disease and vascular dementia: comparison of perfusion and metabolic pattern. Eur J Nucl Med 1994;21:1052–60.PubMed

Ishii K, Sasaki M, Sakamoto S, Yamaji S, Kitagaki H, Mori E. Tc-99m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy-d-glucose PET in Alzheimer’s disease. Comparison of perfusion and metabolic patterns. Clin Nucl Med 1999;24:572–5.CrossRefPubMed

Masterman DL, Mendez MF, Fairbanks LA, Cummings JL. Sensitivity, specificity, and positive predictive value of technetium 99-HMPAO SPECT in discriminating Alzheimer’s disease from other dementias. J Geriatr Psychiatry Neurol 1997;10:15–21.PubMed

Bartenstein P, Minoshima S, Hirsch C, Buch K, Willoch F, Mosch D, Schad D, Schwaiger M, Kurz A. Quantitative assessment of cerebral blood flow in patients with Alzheimer’s disease by SPECT. J Nucl Med 1997;38:1095–101.PubMed

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44.PubMed

10.

Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48.PubMed

11.

Metz CE. ROC methodology in radiologic imaging. Invest Radiol 1986;21:720–33.PubMed

12.

Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 1998;10:271–302.CrossRefPubMed

13.

Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, et al. Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 1999;47:564–9.PubMed

14.

Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology 1999;53:1292–9.PubMed

15.

Hogervorst E, Bandelow S, Combrinck M, Irani S, Smith A. The validity and reliability of 6 sets of clinical criteria to classify Alzheimer’s disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach. Dement Geriatr Cogn Disord 2003;16:170–80.CrossRefPubMed

16.

Sjobeck M, Englund E. Alzheimer’s disease and the cerebellum: a morphologic study on neuronal and glial changes. Dement Geriatr Cogn Disord 2001;12:211–8.CrossRefPubMed

17.

Pickut BA, Dierckx RA, Dobbeleir A, Audenaert K, Van Laere K, Vervaet A, De Deyn PP. Validation of the cerebellum as a reference region for SPECT quantification in patients suffering from dementia of the Alzheimer type. Psychiatry Res 1999;90:103–12.CrossRefPubMed

18.

Heiss WD, Kessler J, Szelies B, Grond M, Fink G, Herholz K. Positron emission tomography in the differential diagnosis of organic dementias. J Neural Transm Suppl 1991;33:13–9.PubMed

19.

Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 1995;19:541–7.PubMed

20.

Blesa R, Mohr E, Miletich RS, Hildebrand K, Sampson M, Chase TN. Cerebral metabolic changes in Alzheimer’s disease: neurobehavioral patterns. Dementia 1996;7:239–45.PubMed

21.

Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer’s disease determined by dynamic FDG-PET. J Nucl Med 1996;37:201–8.PubMed

22.

Rodriguez G, Vitali P, Calvini P, Bordoni C, Girtler N, Taddei G, et al. Hippocampal perfusion in mild Alzheimer’s disease. Psychiatry Res 2000;100:65–74.CrossRefPubMed

23.

Karbe H, Kertesz A, Davis J, Kemp BJ, Prato FS, Nicholson RL. Quantification of functional deficit in Alzheimer’s disease using a computer-assisted mapping program for^99mTc-HMPAO SPECT. Neuroradiology 1994;36:1–6.PubMed

24.

Martin AJ, Friston KJ, Colebatch JG, Frackowiak RS. Decreases in regional cerebral blood flow with normal aging. J Cereb Blood Flow Metab 1991;11:684–9.PubMed

25.

Soonawala D, Amin T, Ebmeier KP, Steele JD, Dougall NJ, Best J, et al. Statistical parametric mapping of^99mTc-HMPAO-SPECT images for the diagnosis of Alzheimer’s disease: normalizing to cerebellar tracer uptake. Neuroimage 2002;17:1193–202.CrossRefPubMed

26.

Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, Kuhl DE, Schwaiger M. Statistical brain mapping of¹⁸F-FDG PET in Alzheimer’s disease: validation of anatomic standardization for atrophied brains. J Nucl Med 2001;42:548–57.PubMed

27.

DeKosky ST, Shih WJ, Schmitt FA, Coupal J, Kirkpatrick C. Assessing utility of single photon emission computed tomography (SPECT) scan in Alzheimer disease: correlation with cognitive severity. Alzheimer Dis Assoc Disord 1990;4:14–23.PubMed

28.

Elgh E, Sundstrom T, Nasman B, Ahlstrom R, Nyberg L. Memory functions and rCBF^99mTc-HMPAO SPET: developing diagnostics in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2002;29:1140–8.CrossRefPubMed

29.

Colloby SJ, Fenwick JD, Williams ED, Paling SM, Lobotesis K, Ballard C, et al. A comparison of^99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging 2002;29:615–22.CrossRefPubMed

30.

Imran MB, Kawashima R, Awata S, Sato K, Kinomura S, Ono S, et al. Tc-99m HMPAO SPECT in the evaluation of Alzheimer’s disease: correlation between neuropsychiatric evaluation and CBF images. J Neurol Neurosurg Psychiatry 1999;66:228–32.PubMed

31.

Hirsch C, Bartenstein P, Minoshima S, Mosch D, Willoch F, Buch K, et al. Reduction of regional cerebral blood flow and cognitive impairment in patients with Alzheimer’s disease: evaluation of an observer-independent analytic approach. Dement Geriatr Cogn Disord 1997;8:98–104.PubMed

32.

Jagust WJ, Haan MN, Reed BR, Eberling JL. Brain perfusion imaging predicts survival in Alzheimer’s disease. Neurology 1998;51:1009–13.PubMed

33.

Ishii K, Mori T, Hirono N, Mori E. Glucose metabolic dysfunction in subjects with a clinical dementia rating of 0.5. J Neurol Sci 2003;15:71–4.CrossRef

34.

Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [¹⁸F]fluorodeoxyglucose. J Comput Assist Tomogr 1983;7:590–8.PubMed

35.

Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920–8.PubMed

36.

Nagata K, Maruya H, Yuya H, Terashi H, Mito Y, Kato H, et al. Can PET data differentiate Alzheimer’s disease from vascular dementia? Ann N Y Acad Sci 2000;903:252–61.PubMed

37.

Steinling M, Defebvre L, Duhamel A, Lecouffe P, Lavenu I, Pasquier F, Charpentier P. Is there a typical pattern of brain SPECT imaging in Alzheimer’s disease? Dement Geriatr Cogn Disord 2001;12:371–8.CrossRefPubMed

38.

Kalaria R. Similarities between Alzheimer’s disease and vascular dementia. J Neurol Sci 2002;203–4:29–34.

39.

Bartels SJ, Horn SD, Smout RJ, Dums AR, Flaherty E, Jones JK, et al. Agitation and depression in frail nursing home elderly patients with dementia: treatment characteristics and service use. Am J Geriatr Psychiatry 2003;11:231–8.CrossRefPubMed

40.

Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387–92.CrossRefPubMed

41.

Hanyu H, Asano T, Kogure D, Abe S, Iwamoto T, Takasaki M. Diagnosis of Alzheimer’s disease using brain SPECT with three-dimensional stereotactic surface projections. Rinsho Shinkeigaku 2001;41:582–7.PubMed

42.

Small GW, Komo S, La Rue A, Saxena S, Phelps ME, Mazziotta JC, et al. Early detection of Alzheimer’s disease by combining apolipoprotein E and neuroimaging. Ann N Y Acad Sci 1996;802:70–8.PubMed

43.

Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752–8.CrossRefPubMed

44.

Kennedy AM, Frackowiak RS, Newman SK, Bloomfield PM, Seaward J, Roques P, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease. Neurosci Lett 1995;186:17–20.CrossRefPubMed

45.

Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94.PubMed

46.

Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer’s disease. J Nucl Med 2002;43:21–6.PubMed

47.

van Dyck CH, Lin CH, Smith EO, Wisniewski G, Cellar J, Robinson R, et al. Comparison of technetium-99m-HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimer’s disease. J Nucl Med 1996;37:1749–55.PubMed

Titel: Diagnosis of suspected Alzheimer’s disease is improved by automated analysis of regional cerebral blood flow
verfasst von: Bich-Ngoc-Thanh Tang
Satoshi Minoshima
Jean George
Annie Robert
Christian Swine
Patrice Laloux
Thierry Vander Borght
Publikationsdatum: 01.11.2004
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2004
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-004-1597-7

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2004

Yearbook of Nuclear Medicine. 2004

Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer’s disease in vivo?

Registration accuracy of 153Gd transmission images of the brain

Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET

99mTc-RBC scintigraphy showing portal vein aneurysm

Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer’s disease in vivo?